-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2024-516253-49-01
4
2025-12-12
advanced/metastatic HER2-positive breast carcinoma
-
2025-521034-28-00
4
2025-12-05
Moderate to Severe Rheumatoid Arthritis (RA)
-
2024-518645-17-00
5
2025-10-07
Blood and lymphatic diseases
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2025-520557-36-00
1
2025-07-24
Advanced Solid Tumors
-
2025-521305-40-00
1
2025-07-22
Participants with Advanced Solid Tumors
-
2024-518359-47-00
10
2025-06-17
Acute Myeloid Leukemia
-
2023-507936-20-00
5
2025-05-05
Acute myeloid leukemia
-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-515506-11-00
4
2025-03-24
Urothelial Carcinoma
-
2024-513317-12-00
5
2025-02-05
Pancreatic cancer
-
2023-506235-15-00
5
2024-11-07
Limited-Stage Small-Cell Lung Cancer (LS SCLC)
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-505678-14-00
4
2024-08-19
Ulcerative Colitis
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2024-512294-26-00
1
2024-04-10
Advanced solid tumors
-
2022-502548-12-00
5
2023-09-28
marginal zone lymphoma
-
2022-501354-10-01
5
2023-06-21
axial spondyloarthritis
-
2023-504254-35-00
7
2023-06-20
Unresectable locally advanced or metastatic solid tumors:
• Clear cell